This meeting took place in 2017



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Engineered Cells and Tissues as Platforms for Discovery and Therapy (K1)


Organizer(s) Laura E. Niklason, Milica Radisic and Nenad Bursac
March 9—12, 2017
Fairmont Copley Plaza • Boston, Massachusetts USA
Discounted Abstract Deadline: Nov 9, 2016
Abstract Deadline: Dec 13, 2016
Scholarship Deadline: Nov 9, 2016
Discounted Registration Deadline: Jan 13, 2017

Sponsored by Editas Medicine, Inc., Juno Therapeutics, Merck & Co., Inc. and Thermo Fisher Scientific Inc.

Summary of Meeting:
Tissue engineering, cell therapies and regenerative medicine have witnessed accelerated progress over the past decade. Fueled by fundamental discoveries in iPS, progenitor, and developmental cell biology, cells are now used as building blocks to create model systems, as testing platforms for drug interventions and as active therapeutics. High-throughput production of various types of “microtissues” or “organoids” is making increasing contributions to our understanding of human development, disease and repair. This Keystone Symposia meeting will highlight these rapidly emerging cell-based tools for fundamental and applied discovery. Culture systems ranging from simple cell cluster organoids, to highly advanced cell-electronic composites, will be discussed. In addition, the encouraging progress that is being made in cell-based therapies across a range of organs and diseases will be featured. The goal of this meeting is to provide a state-of-the-art review of both pluripotent and differentiated cells as tools for discovery and therapy. A broad range of cell types and therapeutic areas will be included.

View Meeting Program

Scholarships/Awards

Keystone Symposia Future of Science Fund Scholarship Recipients

Adriana Blazeski
Johns Hopkins University, USA

Ryan LaRanger
University of Texas Southwestern Medical Center, USA

Alex Ng
Harvard Medical School, USA